Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

  • ICON7 investigators

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science